Research programme: CXCR2 targeting therapeutics - Salipro Biotech
Latest Information Update: 26 Jul 2024
At a glance
- Originator Salipro Biotech
- Class Antineoplastics
- Mechanism of Action Interleukin 8B receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 01 Jul 2024 Research programme: CXCR2 targeting therapeutics - Salipro Biotech is available for licensing as of 01 Jul 2024. https://www.salipro.com/partnering
- 01 Jul 2024 Early research in Cancer in Sweden (unspecified route), prior to July 2024 (Salipro Biotech pipeline, July 2024)